NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
28 Jun 2012

Ysios Capital leads a € 2M Series A round of Inbiomotion

Barcelona June 28, 2012 –Ysios Capital, a leading Spanish life sciences venture capital firm, today announces that it has led the €2 million Series A financing of Inbiomotion SL, a spin-out company from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA focused on the development of biomarkers for the prediction of bone metastasis from primary tumor biopsies.
13 Jun 2012

Endosense completes enrollment in toccastar ide study of its Tacticath force-sensing ablation catheter

GENEVA – June 13, 2012 - Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.
12 Jun 2012

Endosense announces ce mark approval, first clinical use of the New tacticath® quartz force-sensing ablation catheter

GENEVA – June 12, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its TactiCath Quartz force-sensing ablation catheter has been CE mark approved.
08 Jun 2012

TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect®

Leuven (BELGIUM) – June 8, 2012 – TiGenix (NYSE Euronext: TIG) announced today that its innovative cartilage repair therapy ChondroCelect® has obtained national reimbursement in the Netherlands.
29 May 2012

Cristina Garmendia returns to Ysios Capital as Partner

Barcelona – 29th May, 2012 – Ysios Capital Partners, a venture capital firm specialized in healthcare and biotechnology, today announces that Dr. Cristina Garmendia returns to the management team after her stage as Minister for Science and Innovation of Spain.
15 May 2012

TiGenix Reports Business & Financial Results for the First Quarter 2012

Leuven (BELGIUM) – May 15, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today gave a business update and announced the financial results for the first quarter ending March 31, 2012.
14 May 2012

Endosense reports strong momentum for contact-force sensing in catheter ablation at heart rhythm 2012.

GENEVA - May 14, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has reported another year of significant advancement in the move toward making contact-force sensing a standard of care in catheter ablation procedures.
24 Apr 2012

TiGenix obtains manufacturing license for European production facility

Leuven (BELGIUM) – April 24, 2012 – TiGenix (NYSE Euronext: TIG) announced today that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands.
17 Apr 2012

TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle.

Leuven (BELGIUM), Madrid (SPAIN) – April 17, 2012 – TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the third cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining patients of this cohort.
14 Apr 2012

TiGenix appoints Dr. Guido Schopen as vice president commercial operations.

Leuven (Belgium) – April 10, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today announced the appointment of Dr. Guido Schopen as vice president commercial operations.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.